(I'm not basing the combo with my last two topics, these just are new releases that are hopefully helping others)
New research on the combo:
http://www.eurekalert.org/pub_releases/2015-01/hlmc-mrd011215.php
Moffitt Cancer Center researchers have discovered a mechanism that leads to resistance to targeted therapy in melanoma patients and are investigating strategies to counteract it. Targeted biological therapy can reduce toxicity and improve outcomes for many cancer patients, when compared to the adverse effects of standard chemotherapeutic drugs. However, patients often develop resistance to these targeted therapies, resulting in more aggressive cells that can spread to other sites or cause regrowth of primary tumors.
Moffitt researchers found that patients who are on B-Raf inhibitor drugs develop more new metastases than patients who are on standard chemotherapy.
They found that melanoma cells that are resistant to B-Raf inhibitors tend to be more aggressive and invasive, thereby allowing the tumor to spread to a new organ site.
My wife has had a good benefit from the combo when she urgently needed them to work. However, she came out of the treatment (when resistance occured) with new and aggressively spreading mets – so although N=1, this does sound familiar and makes me regret in hindsight that we didn't move to immonutherapie before resistance occured.
.
